Aptuit: Cyxone assigns Aptuit for the capsulation of Phase II candidate Rabeximod

Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the company has signed an agreement with Aptuit, an Evotec company, to perform the capsulation of the Rabeximod substance. This is a key step in the preparation of the planned Phase IIb study, in which patients will be administered capsules with Rabeximod, therefore securing a further step in the Rabeximod Phase IIb program. Malin Berthold, Head of Project Management at Cyxone, comments "We are glad to enter this partnership with Aptuit. They were responsible for the successful capsulation for the previous 12-week